There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Peritoneal carcinomatosis is a common cause of death in pancreatic cancer patients.
In this metastatic stage of the disease, few patients show a sustained response to
therapy. In the palliative situation, targeted and compartment restricted delivery
of drugs offers the opportunity to focus drugs directly to the tumor site, which is
a prerequisite for avoiding toxic side effects. Here, we demonstrate the therapeutic
efficiency of biocompatible polyvinyl-alcohol hydrogel drug eluting beads (DEBs) containing
doxorubicin, mitoxantrone and irinotecan in vitro and in vivo in a syngenic model
of experimental pancreatic cancer.